Clinical Trial Update: 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 3-AP (triapine) with cisplatin in patients with recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• 3-AP (Triapine) (3-aminopyridine-2-carboxaldehyde thiosemicarbazone)
• CISPLATIN (cisplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED